Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002599447 | SCV003497456 | uncertain significance | Bardet-Biedl syndrome | 2022-03-20 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 622 of the BBS2 protein (p.Arg622Gln). This variant is present in population databases (rs759714501, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with BBS2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Dept Of Ophthalmology, |
RCV003889246 | SCV004705053 | uncertain significance | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Fulgent Genetics, |
RCV005021593 | SCV005643995 | uncertain significance | Bardet-Biedl syndrome 2; Retinitis pigmentosa 74 | 2024-06-10 | criteria provided, single submitter | clinical testing |